Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.
In modern oncology, important insights from clinical trials often emerge years after initial publication. As new therapies extend survival and transition more patients into long-term remissions, clinicians and researchers are increasingly looking beyond initial response rates to understand durability, long-term safety, and even the possibility of a cure.
